v3.26.3
Collaboration Agreements (Tables)
9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue, Cost of Revenues, and Expense The following table summarizes the Company’s proportionate share of the activity under the Biogen Collaboration Agreement:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
(unaudited)
(unaudited)
Collaboration revenue (ZURZUVAE)
$41,697 $20,164 $104,690 $20,164 
Cost of revenues
641 434 2,967 434 
Research and development expenses
504 (928)1,797 (928)
Selling, general and administrative expenses
27,998 13,561 77,907 13,561